scholarly journals St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment

Breast Care ◽  
2019 ◽  
Vol 14 (2) ◽  
pp. 103-110 ◽  
Author(s):  
Marija Balic ◽  
Christoph Thomssen ◽  
Rachel Würstlein ◽  
Michael Gnant ◽  
Nadia Harbeck
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Early Breast Cancer ◽  
Patient Empowerment ◽  
Breast Cancer Treatment ◽  
Consensus Conference ◽  
Great Success ◽  
Main Theme ◽  
Treatment Standards ◽  
The Impact

This year, the St. Gallen Consensus Conference on early breast cancer treatment standards took place for the third time in Vienna, Austria, which is where the next conference will also take place (next date: March 17–20, 2021!). Once again, more than 3,000 participants from over 100 countries came together, and, overall, the 2019 St. Gallen/Vienna conference was a great success. After 3 days of reviews conducted by a global faculty concerning the most important evidence published in the last 2 years, the Consensus votes’ challenge was to define the impact on routine everyday practice. This year, the conference’s main theme was the optimization of early breast cancer therapies by assessment of the magnitude of benefit, aiming at further refinement when compared to de-escalation and escalation, which were mainly the topic of the 2017 conference. Patient empowerment and the importance of shared decision-making were particularly emphasized. The traditional panel votes were moderated by Eric Winer from Harvard, and for the most part, they managed to clarify most of the critical questions. This brief report by Editors of Breast Care summarizes the results of the 2019 international panel votes with respect to locoregional and systemic treatment as a quick news update for our readers, but it expressly does not intend to replace the official St. Gallen Consensus publication that will follow shortly in Annals of Oncology.

scholarly journals St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment

Breast Care ◽  
2017 ◽  
Vol 12 (2) ◽  
pp. 101-106 ◽  
Author(s):  
Michael Gnant ◽  
Nadia Harbeck ◽  
Christoph Thomssen
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Axillary Dissection ◽  
Neoadjuvant Treatment ◽  
Breast Conserving Therapy ◽  
Breast Cancer Treatment ◽  
Consensus Conference ◽  
Main Theme ◽  
Treatment Standards ◽  
Neoadjuvant Systemic Therapy

For the second time, the St. Gallen Consensus Conference on early breast cancer treatment standards took place in Vienna, Austria, where it will remain for the foreseeable future (next date: March 20-23, 2019). With the probably most prominent line-up of global breast cancer experts and more than 3,000 participants from over 100 countries, the 2017 St. Gallen/Vienna conference again was a huge success. A generation change took place with respect to the Conference Co-Chairpersons. Traditionally, the experts from all continents reviewed publications from the past 2 years, and discussed whether new diagnostic or therapeutic means were ready for routine everyday practice. This year, the conference's main theme was ‘Escalating and Deescalating Treatment', and the traditional panel votings clarified a number of issues in this respect. Several subjects of all breast cancer modalities were further de-escalated (surgery: ‘no ink on tumor' clearly confirmed as standard; resection within new limits after neoadjuvant systemic therapy; axillary dissection may also be avoided after mastectomy under certain circumstances; radiotherapy: hypofractionation is standard of care in breast conserving therapy; chemotherapy: can be avoided in low-risk patients). However, others were escalated: surgery: after neoadjuvant treatment and after mastectomy a positive sentinel node leads to axillary dissection; radiotherapy: regional nodes have to be irradiated in 4+ nodes situations; adjuvant therapy: bisphosphonates as standard for postmenopausal women. There was no clear panel opinion on the optimal use of multigenomic assays. As always, the panel recommendations are strictly opinion-based, and try to depict the ‘usual' treatment for the ‘average' patients. This rapid report by the editors-in-chief of Breast Care summarizes the results of the 2017 international panel votings with respect to loco-regional systemic treatment, and does not intend to replace the official St. Gallen Consensus publication.

scholarly journals The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Mads G. Jørgensen ◽  
Navid M. Toyserkani ◽  
Frederik G. Hansen ◽  
Anette Bygum ◽  
Jens A. Sørensen
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Treatment ◽  
Breast Cancer Treatment ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
The Impact

AbstractThe impact of breast cancer-related lymphedema (BCRL) on long-term quality of life is unknown. The aim of this study was to investigate the impact of BCRL on health-related quality of life (HRQoL) up to 10 years after breast cancer treatment. This regional population-based study enrolled patients treated for breast cancer with axillary lymph node dissection between January 1st 2007 and December 31th 2017. Follow up and assessments of the included patients were conducted between January 2019 and May 2020. The study outcome was HRQoL, evaluated with the Lymphedema Functioning, Disability and Health Questionnaire, the Disabilities of the Arm, Shoulder and Hand Questionnaire and the Short Form (36) Health Survey Questionnaire. Multivariate linear logistic regression models adjusted for confounders provided mean score differences (MDs) with 95% confidence intervals in each HRQoL scale and item. This study enrolled 244 patients with BCRL and 823 patients without BCRL. Patients with BCRL had significantly poorer HRQoL than patients without BCRL in 16 out of 18 HRQoL subscales, for example, in physical function (MDs 27, 95%CI: 24; 30), mental health (MDs 24, 95%CI: 21; 27) and social role functioning (MDs 20, 95%CI: 17; 23). Age, BMI, BCRL severity, hand and dominant arm affection had only minor impact on HRQoL (MDs < 5), suggesting a high degree of inter-individual variation in coping with lymphedema. This study showed that BCRL is associated with long-term impairments in HRQoL, especially affecting the physical and psychosocial domains. Surprisingly, BCRL diagnosis rather than clinical severity drove the largest impairments in HRQoL.

scholarly journals Data-Driven Treatment Pathways Mining for Early Breast Cancer Using cSPADE Algorithm and System Clustering

2020 ◽  
Author(s):  
Qing Yang ◽  
Ting Luo ◽  
Wei Zhang ◽  
Xiaorong Zhong ◽  
Ping He ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Early Breast Cancer ◽  
Breast Cancer Treatment ◽  
Breast Cancer Patients ◽  
Treatment Pathways ◽  
Kolmogorov Smirnov ◽  
System Clustering ◽  
Sequence Rules ◽  
Smirnov Test

Abstract Background: Due to the multidimensional, multilayered, and chronological order of the cancer data in this study, it was challenging for us to extract treatment paths. Therefore, it was necessary to design a new data mining scheme to effectively extract the treatment path of breast cancer. To determine whether the cSPADE algorithm and system clustering proposed in this study can effectively identify the treatment pathways for early breast cancer. Methods: We applied data mining technology to the electronic medical records of 6891 early breast cancer patients to mine treatment pathways. We provided a method of extracting data from EMR and performed three-stage mining: determining the treatment stage through the cSPADE algorithm → system clustering for treatment plan extraction → cSPADE mining sequence pattern for treatment. The Kolmogorov-Smirnov test and correlation analysis were used to cross-validate the sequence rules of early breast cancer treatment pathways.Results: We unearthed 55 sequence rules for early breast cancer treatment, 3 preoperative neoadjuvant chemotherapy regimens, 3 postoperative chemotherapy regimens, and 2 chemotherapy regimens for patients without surgery. Through 5-fold cross-validation, Pearson and Spearman correlation tests were performed. At the significance level of P <0.05, all correlation coefficients of support, confidence and lift were greater than 0.89. Using the Kolmogorov-Smirnov test, we found no significant differences between the sequence distributions.Conclusions: The cSPADE algorithm combined with system clustering can achieve hierarchical and vertical mining of breast cancer treatment models. By uncovering the treatment pathways of early breast cancer patients by this method, the real-world breast cancer treatment behavior model can be evaluated, and it can provide a reference for the redesign and optimization of the treatment pathways.

77 The impact of the boost type (E−, IR-192 HDR) on the cosmetic result in conservative breast cancer treatment

1994 ◽  
Vol 31 ◽  
pp. S41 ◽  
Author(s):  
J. Hammer ◽  
C. Track ◽  
B. Pakisch ◽  
D.H. Seewald ◽  
J.P. Zoidl ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Breast Cancer Treatment ◽  
Cosmetic Result ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document